INTRODUCTION
============

Nonalcoholic fatty liver disease (NAFLD) has become a leading cause of chronic liver disease, cirrhosis, type 2 diabetes mellitus (T2DM), and liver-related mortality \[[@B1][@B2]\]. In addition, the presence of NAFLD is associated with higher morbidity and mortality of cardiovascular disease (CVD) than the absence of NAFLD \[[@B3]\].The liver develops fibrosis as a wound-healing process after various kinds of liver injury \[[@B4]\]. Recently, emerging data have suggested that the degree of fibrosis in the presence of NAFLD is an important prognostic factor for future liver-related outcomes and mortality and is associated with the cardiometabolic risk \[[@B5][@B6]\].

Obesity is highly correlated not only with the NAFLD prevalence and but also with histologic severity \[[@B7][@B8]\]. It is well known that abdominal obesity, especially high visceral adipose tissue (VAT), plays an important role in the development of metabolic diseases and NAFLD independent of generalized obesity \[[@B7][@B9]\]. Previous studies have demonstrated that VAT is clearly associated with NAFLD. On the other hand, the role of subcutaneous adipose tissue (SAT) in NAFLD is controversial, in that some studies suggested no relationship between SAT and NAFLD \[[@B10]\], and others reported an inverse relationship \[[@B11][@B12][@B13][@B14]\]. Considering the independent effects of both VAT and SAT on the cardiometabolic risk, the relative distribution of body fat might be more important than VAT or SAT *per se*. Consequently, the visceral-to-subcutaneous fat ratio (VSR) has been proposed to be a better predictor of atherosclerosis and cardiometabolic risk not only in the asymptomatic general population and obese subjects but also in patients with T2DM \[[@B15][@B16][@B17][@B18]\]. However, there are few available studies about the contribution of VSR to NAFLD and liver fibrosis in the general population \[[@B14]\].

Further, although NAFLD is highly associated with obesity, it is also known to be prevalent in nonobese subjects \[[@B19]\]. A meta-analysis study demonstrated that lean and obese subjects with NAFLD share a common altered metabolic and cardiovascular profile \[[@B8]\]. Relative to lean individuals without NAFLD, the lean population with NAFLD showed an excess of abdominal adipose tissue \[[@B20]\]. In particular, studies showing whether body fat distribution, represented by VSR, has a diagnostic value in identifying multiple metabolic risk factors in nonobese subjects, compared with visceral fat area (VFA) and subcutaneous fat area (SFA), are rare. A previous study revealed that VSR showed superior diagnostic value in predicting multiple risk factors in subjects with normal waist circumference and proved that it was superior to VFA \[[@B15]\].

To our knowledge, few studies have examined whether the quartiles of VSR assessed using fat-computed tomography (CT) are associated with advanced fibrosis in the general population with NAFLD. We hypothesized that body fat distribution represented by VSR would indicate the risk for the presence of NAFLD and for advanced fibrosis in individuals with NAFLD. Therefore, we investigated the association of VSR quartiles measured using fat-CT with NAFLD and the probability of advanced fibrosis in the presence of NAFLD by using the fibrosis (FIB-4) score and aspartate aminotransferase (AST)-to-platelet (PLT) ratio index (APRI) in healthy Korean adults. In addition, we further analyzed this association according to the presence or absence of obesity.

METHODS
=======

Study design and study participants
-----------------------------------

In this cross-sectional study, we recruited participants from the Kangbuk Samsung Health Study, a program of the Health Promotion Center of Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. The purpose of the medical health checkup program is to promote the health of employees through regular health examinations and to enable the early detection of diseases. Most of the examinees are employees of various industrial companies throughout the country, and their family members. The medical examinations are largely paid for by the employers, and a considerable proportion of the examinees undergo examinations annually or biennially.

The present analysis included participants who underwent fat-CT during the health checkup program between January 2013 and December 2017 (*n*=10,229). Of these 10,229 subjects, we excluded those with alcohol intake of ≥30 g/day for men or ≥20 g/day for women (*n*=1,574); use of steatogenic medications within the past year, such as valproate, amiodarone, methotrexate, tamoxifen, or corticosteroids (*n*=30); known liver disease or current use of medications for liver disease (*n*=297); positive serologic markers for hepatitis B virus or hepatitis C virus (*n*=288); history of liver cirrhosis or findings of liver cirrhosis on ultrasonography (*n*=2); and missing data on alcohol status, abdominal ultrasonography, body mass index (BMI), high-sensitivity C-reactive protein (hs-CRP), or homeostasis model assessment of insulin resistance (HOMA-IR) (*n*=2,771). Final analyses were performed in 7,465 subjects.

This study was approved by the Institutional Review Board of Kangbuk Samsung Hospital (KBSMC 2018-11-003), which waived the requirement for informed consent because we only retrospectively accessed a de-identified database for analysis purposes.

Diagnosis of NAFLD and measurement of abdominal fat area
--------------------------------------------------------

All subjects underwent abdominal ultrasonography (Logic Q700 MR, GE, Milwaukee, WI, USA). Fatty liver was diagnosed according to standard criteria, including hepatorenal echo contrast, liver brightness, and vascular blurring on ultrasonography with a 3.5-MHz probe, which was conducted by experienced radiologists blinded to the aim of this study and the clinical status of the subjects \[[@B21]\]. NAFLD was defined as the detection of fatty liver in the absence of other etiologies of hepatic steatosis, as described in the exclusion criteria. Of the final 7,465 subjects, 2,706 were diagnosed with NAFLD on ultrasonography.

Abdominal VFA and SFA were measured by CT (a Lightspeed VCT XTe-64 slice Multi-detector CT scanner, GE Healthcare, Tokyo, Japan) \[[@B22]\]. A cross-sectional scan at 10 mm thickness centered at the L4-L5 vertebral disc space, with the subject in the supine position, was obtained using a radiograph of the skeleton as a reference to establish the position of the scans to the nearest millimeter. SFA and VFA boundaries were defined using a manual cursor by delineating these areas with a graph pen. The adipose tissue areas were calculated by computing the fat area surfaces with an attenuation range of −190 to −30 Hounsfield units. The abdominal VFA was measured by drawing a line in the muscle wall surrounding the abdominal cavity. The SFA was calculated by subtracting the VFA from the total fat area. Then the VSR was calculated.

Estimating the risk of advanced fibrosis in NAFLD
-------------------------------------------------

In subjects with NAFLD, FIB-4, and APRI as serum markers of fibrosis were used to estimate the degree of advanced fibrosis \[[@B23]\]. The FIB-4 score includes readily available clinical data of age, AST, alanine aminotransferase (ALT), and PLT, and was validated for use in NAFLD by Shah et al. \[[@B24]\]. The FIB-4 score was calculated using the following formula: FIB-4=\[age (yr)×AST (IU/L)\]/{\[PLT (10^9^/L)\]×\[ALT (IU/L)^2^\]}. The cutoffs for low, intermediate, and high probability of advanced fibrosis were \<1.3, 1.3 to 2.67, and \>2.67, respectively. The APRI is another simple index for identifying patients with advanced fibrosis (≥F3) and was calculated using the following formula: APRI=\[AST/AST (upper limit of normal)\]/PLT (×10^9^/L) \[[@B25][@B26]\]. We used the cutoff of 0.5 for low probability and 1.5 for high probability of advanced fibrosis.

Covariates and baseline anthropometric and laboratory measurements
------------------------------------------------------------------

The values of serum biochemical parameters and physical measurements were obtained by trained staff during health examinations, and data on medical history, medication use, and health-related behaviors were collected through a self-administered questionnaire. BMI was calculated by dividing weight (kg) by the square of height (m^2^). Systolic blood pressure and diastolic blood pressure were measured three times with the subjects in a seated position and with a 1-minute rest between each measurement. The average of the second and third measurements was used in our analyses.

Blood samples were collected after 12 hours of overnight fasting. Fasting plasma glucose levels were determined through the hexokinase method (Modular D2400, Hitachi, Tokyo, Japan). An electrochemiluminescence immunoassay was used to assess fasting insulin levels (Modular E170, Hitachi). An enzymatic colorimetric test was used to measure the total cholesterol and triglyceride levels. The selective inhibition method was used to measure high density lipoprotein cholesterol levels, and a homogeneous enzymatic colorimetric test was used to measure low density lipoprotein cholesterol levels. ALT, AST, and gamma-glutamyltransferase were measured using Bayer Reagent Packs on an automated chemistry analyzer (Advia 1650 autoanalyzer, Bayer Diagnostics, Leverkusen, Germany). Serum hs-CRP levels were measured using a nephelometric assay with a BNII nephelometer (Dade Behring, Deerfield, IL, USA). Insulin resistance was measured using the HOMA-IR and was obtained by applying the following formula: HOMA-IR=fasting insulin (µIU/mL)×fasting blood glucose (mmol/L)/22.5 \[[@B27]\].

A smoker was defined as a subject who had smoked at least five packs of cigarettes over the course of the lifetime. Regular exercise was defined as moderate-intensity exercise at least three times every week.

Total energy and nutrient intake was calculated by using food composition table developed by the Korean Nutrition Society \[[@B28]\]. Education level and history of CVD were evaluated using self-reported questionnaire.

Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, self-reported history of hypertension, or current use of antihypertensive medications. The presence of diabetes was defined as fasting plasma glucose level ≥126 mg/dL or hemoglobin A1c level ≥6.5%, a self-reported history of diabetes, or current use of antidiabetic medication \[[@B29]\].

Statistical analysis
--------------------

The characteristics of the study participants were examined according to VSR quartiles. To test for linear trends, category numbers were used as continuous variables in regression models. The study population was grouped into quartiles of VSR, as follows: Q1 (\<0.37), Q2 (0.37 to 0.51), Q3 (0.52 to 0.70), and Q4 (≥0.71).

To evaluate the association of NAFLD across quartiles of VSR, SFA, and VFA, we used Poisson regression with robust variance to estimate prevalence ratios (PRs) with 95% confidence intervals (CIs) for NAFLD. Models were initially adjusted for age and sex, and further adjusted for center (Seoul or Suwon), year of screening examination, smoking status (never, past, current, or unknown), physical activity, alcohol intake (0, \<10, \>10 g/day, or unknown), total energy intake (in quintile or unknown), education level, history of CVD, history of diabetes, and history of hypertension (model 1). To investigate whether this association was influenced by obesity or insulin resistance, we performed additional analysis with adjustment for BMI and HOMA-IR in model 2. We also estimated the PRs of NAFLD with the degree of fibrosis based on FIB-4 or APRI by VSR quartiles, by using multinomial logistic regression models as outcomes categorized into no NAFLD, NAFLD plus low FIB-4 or APRI, and NAFLD plus intermediate/high FIB-4 or APRI. Multivariable models 1 and 2 were adjusted with the same variables described above. To determine the linear trends of prevalence, the number of quartiles was used as a continuous variable and tested on each model.

We performed stratified analyses in prespecified subgroups defined by BMI (\<25 kg/m^2^ vs. ≥25 kg/m^2^). Interactions between subgroups were tested using likelihood ratio tests comparing models with and without multiplicative interaction terms. All *P* values were two-tailed, and values of *P*\<0.05 were considered statistically significant. We used STATA version 14.0 (Stata Corp., College Station, TX, USA) for data analysis.

RESULTS
=======

General characteristics of the participants according to VSR quartiles
----------------------------------------------------------------------

The total number of subjects was 7,465 (5,532 men and 1,933 women), and their mean age was 35.7 years ([Table 1](#T1){ref-type="table"}). The subjects were subdivided into four groups according to VSR quartiles. The baseline characteristics according to VSR quartiles are presented in [Table 1](#T1){ref-type="table"}.

The proportion of men, subjects with a history of diabetes, subjects with hypertension, and subjects with CVD significantly increased across VSR quartiles. BMI, insulin resistance, and the mean values of glucose and traditional and nontraditional cardiovascular risk factors (blood pressure, lipid profile, and hs-CRP) significantly increased across VSR quartiles. The AST level, ALT level, FIB-4, and APRI significantly increased across VSR quartile groups.

Risk of incident NAFLD across quartiles of VSR, SAT, and VAT
------------------------------------------------------------

Of the total 7,465 subjects, 2,706 (36.2%) were diagnosed with NAFLD on ultrasonography. [Table 2](#T2){ref-type="table"} presents the risk of incident NAFLD across the quartiles of VSR. In age- and sex-adjusted models, the PRs for NAFLD comparing Q2 to Q4 withQ1 of VSR were 1.4 (95% CI, 1.23 to 1.59), 1.67 (95% CI, 1.47 to 1.89), and 1.75 (95% CI, 1.54 to 1.99), respectively. After further adjusting for confounding variables including examination center, year of screening examination, smoking status, physical activity, alcohol intake, education level, history of CVD, history of diabetes, and history of hypertension, significantly increased PRs were sustained across the groups. The results were strengthened after additional adjustment for BMI and HOMA-IR (1.54 vs. 1.95 vs. 2.24). When the analyses were performed according to gender after excluding 151 subjects with diabetes, women showed higher PRs in all analyses compared with men, although the observed trends were similar ([Supplemental Table S1](#S1){ref-type="supplementary-material"}).

The PRs of NAFLD were analyzed according to quartiles of SAT and VAT ([Table 2](#T2){ref-type="table"}). The prevalence of NAFLD also significantly increased across the quartiles of subcutaneous and visceral fat.

Prevalence of NAFLD and degree of fibrosis based on fibrosis scores according to VSR quartiles
----------------------------------------------------------------------------------------------

We assessed the degree of advanced fibrosis in subjects with NAFLD based on FIB-4 and APRI, and categorized the subjects into having a low, intermediate, or high probability of fibrosis. [Table 3](#T3){ref-type="table"} shows the association between VSR quartiles and the degree of advanced fibrosis assessed by FIB-4 in NAFLD by using multinomial logistic regression. The age- and sex-adjusted PRs (95% CI) for NAFLD with low FIB-4 comparing Q2 to Q4 with Q1 of VSR increased steadily (1.51 \[95% CI, 1.27 to 1.8\], 2.0 \[95% CI, 1.67 to 2.38\], and 2.19 \[95% CI, 1.81 to 2.64\], respectively). This association also persisted even after further adjustment for the above-mentioned confounders in model 1 and for BMI and HOMA-IR (2.23 \[95% CI, 1.8 to 2.76\], 3.8 \[95% CI, 3.04 to 4.73\], and 5.26 \[95% CI, 4.15 to 6.68\], respectively). With respect to the PRs for NAFLD with intermediate or high FIB-4, the age- and sex-adjusted PRs substantially increased across VSR quartiles (1.7 \[95% CI, 0.34 to 8.59\] for Q2, 3.48 \[95% CI, 0.76 to 15.89\] for Q3, and 5.79 \[95% CI, 1.28 to 26.14\] for Q4, respectively). The results were strengthened after multivariable adjustment including model 1 plus BMI and HOMA-IR (19.34 \[95% CI, 4.06 to 92.18\] for Q4; *P* for trend \<0.001).

[Table 4](#T4){ref-type="table"} shows the association between VSR quartiles and the degree of advanced fibrosis based on APRI in subjects with NAFLD. The results were similar to those based on FIB-4. The PRs (95% CI) for NAFLD with low APRI comparing Q2, Q3, and Q4 with Q1 of VSR moderately increased after multivariate covariate adjustment (1.45 \[95% CI, 1.21 to 1.73\], 1.96 \[95% CI, 1.64 to 2.35\], and 2.1 \[95% CI, 1.73 to 2.55\], respectively). This association persisted even after further adjustment for BMI and HOMA-IR (2.14 \[95% CI, 1.72 to 2.65\], 3.67 \[95% CI, 2.94 to 4.58\], and 4.99 \[95% CI, 3.93 to 6.33\], respectively). In addition, the risk for NAFLD with intermediate or high APRI significantly increased across VSR quartiles and was strengthened after further adjustments for BMI and HOMA-IR (5.04 \[95% CI, 2.65 to 9.59\], 7.51 \[95% CI, 3.91 to 14.42\], and 19.55 \[95% CI, 9.97 to 38.34\], respectively).

Prevalence of NAFLD and degree of fibrosis by VSR quartiles according to obesity
--------------------------------------------------------------------------------

The association of VSR quartiles with NAFLD and the risk for advanced fibrosis was also examined by subgroups of study participants according to obesity ([Table 5](#T5){ref-type="table"}). These associations of VSR quartiles with NAFLD and the intermediate to high probability of advanced fibrosis in NAFLD were modified by obesity (*P* for interaction \<0.01). High VSR values were more strongly associated with the prevalence of NAFLD in nonobese than in obese subjects. In addition, the associations between VSR values and the intermediate to high probability of advanced fibrosis assessed by FIB-4 in NAFLD were stronger in obese than in nonobese subjects. With respect to the PRs for advanced fibrosis based on APRI, the results were similar to those for FIB-4.

DISCUSSION
==========

The results of the present cross-sectional study show that high VSR is an independent risk factor for the presence of NAFLD and advanced fibrosis even after adjustment for BMI and insulin resistance. In a subgroup analysis according to obesity, VSR was well associated with NAFLD even in nonobese subjects and the PR for NAFLD was higher in the nonobese than in the obese group. Concerning the probability of advanced fibrosis, higher VSR was more strongly associated with an intermediate to high probability of advanced fibrosis, especially in the obese group.

Previous epidemiologic, cross-sectional, and longitudinal studies demonstrated that VAT is clearly associated with NAFLD, whereas the role of SAT in NAFLD remains inconclusive \[[@B11]\]. Some studies showed that SAT is correlated with NAFLD, whereas others did not find this correlation \[[@B12]\]. However, there are few studies about the association of VSR and NAFLD and the degree of advanced fibrosis \[[@B12][@B14]\]. In a study of 38 patients with biopsy-proven NAFLD by van der Poorten et al. \[[@B12]\], VSR assessed using magnetic resonance imaging also had an association with increasing fibrosis stage, although the extent of association was less than that of visceral fat. VSR has a moderate negative correlation with adiponectin and leptin but shares similar associations to visceral fat. In addition, subcutaneous fat is not associated with increasing steatosis, inflammation, or fibrosis, indicating its metabolically protective properties. Kim et al. \[[@B14]\] investigated the longitudinal association between VAT versus SAT and the incidence and regression of NAFLD in 2017 individuals who participated in a voluntary follow-up health screening with a 4.43-year of median follow-up. They showed that an increased VAT area was associated with a higher incidence of NAFLD and an increased SAT area was significantly associated with regression of NAFLD in multivariable analysis. Consistent with our study, their study showed that the VSR was strongly associated with incident NAFLD in the fully adjusted multivariate model. However, they did not investigate the association with fibrosis.

Obesity is highly correlated not only with NAFLD prevalence but also with histologic severity. In a systematic review and meta-analysis using cross-sectional data of patients with biopsy-proven nonalcoholic steatohepatitis (NASH) and those with no NASH, being overweight or obese was associated with more severe histologic features \[[@B8]\]. Although the mechanisms underlying the association between excessive adiposity or fat gain and the progression of fibrosis are not yet fully understood, insulin resistance and inflammation are believed to be involved \[[@B30][@B31][@B32]\]. However, after adjustment for insulin resistance represented by HOMA-IR, the association between VSR and the risk of advanced fibrosis remained significant in the present study. Multiple other factors, including lipotoxicity, inflammatory attacks by proinflammatory cytokines, adipocytokines, and oxidative stress, may lead to the development of fibrosis in a substantial proportion of the population with NAFLD \[[@B31][@B33]\].

In this study, higher VSR was significantly and independently associated with a higher risk of NAFLD development even after adjustment for confounders including BMI (as a simple indicator of obesity). In the subgroup analysis according to obesity, the predictive value of VSR for the risk of NAFLD was stronger in the nonobese group than in the obese group. The growing prevalence of NAFLD (around 8% to 19%) in lean Asians with BMI \<25 kg/m^2^ has been reported, compared with the prevalence of −7% in the United States population \[[@B34][@B35]\]. In a meta-analysis, lean and obese subjects with NAFLD showed similar altered metabolic and cardiovascular profiles \[[@B8]\]. Relative to lean subjects without NAFLD, the lean NAFLD population showed an excess of abdominal adipose tissue. In particular, studies on whether the body fat distribution (represented by VSR) has diagnostic value in identifying multiple metabolic risk factors in nonobese subjects, compared with VFA and SFA, are rare. One previous study revealed that VSR showed superior diagnostic value in predicting multiple risk factors in subjects with normal waist circumference, and proved that it is superior to VFA \[[@B15]\].

Whether nonobese individuals with NAFLD are protected from severe histologic outcomes is unknown. In our study, both nonobese and obese subjects with NAFLD exhibited a high risk of advanced fibrosis across VSR quartiles. Nonetheless, obese NAFLD subjects showed higher odds of having a higher risk for advanced fibrosis according to VSR quartiles than nonobese NAFLD subjects. Some previous studies reported findings similar to our results. A meta-analysis showed that overweight/obese NAFLD subjects based on BMI showed significantly higher fibrosis scores relative to lean subjects (BMI ≤25 kg/m^2^) with NAFLD \[[@B8]\]. Previously, our group evaluated the association of baseline BMI and weight change with fibrosis progression, determined by APRI, in a prospective large cohort study on NAFLD \[[@B36]\]. We found obesity and weight gain to be independently associated with an increased risk of fibrosis progression, from a low to an intermediate or a high probability of advanced fibrosis.

This study has several limitations. First, NAFLD and liver fibrosis were diagnosed using ultrasonography and calculated indices, not with biopsy. Furthermore, we could not consider the severity of NAFLD diagnosed with ultrasonography due to relative imperfectness of ultrasonography to diagnose fatty liver. Although liver biopsy is required for an accurate diagnosis and staging of liver fibrosis, it is not practical to perform liver biopsies in all low-risk individuals, because of several challenges such as sampling errors, intra-observer variations, invasiveness, and risk of complication \[[@B37]\]. Therefore, simple serum-based noninvasive scoring systems such as FIB-4 and APRI have been developed and validated to identify and exclude advanced fibrosis in patients with NAFLD, and have been proven to correlate well with liver histology \[[@B23][@B38][@B39]\]. In addition, evidence for advanced fibrosis as determined using noninvasive scoring systems and markers is useful in predicting the increased risk of liver-related complications and cardiovascular mortality \[[@B40][@B41]\]. Second, as this was a cross-sectional study, the causal relationship between VSR and NAFLD or advanced fibrosis in NAFLD cannot be determined. Third, the generalization of our findings may be limited by the study population comprising young and middle-aged healthy Koreans. Lastly, as the information regarding the menopausal status of the female participants were not accurate, we could not analyze the data of pre- and postmenopausal women separately. Although the strength of this study is the large sample size, we could not perform stratified subgroup analyses with the PR of the low risk of fibrosis according to VSR quartiles in the obese group because of the small number of obese subjects with a low risk of fibrosis.

In conclusion, we have demonstrated that VSR is associated with NAFLD and advanced fibrosis, based on FIB-4 or APRI, in subjects with NAFLD. This effect was independent of age, sex, insulin resistance, and obesity. In stratified analysis, VSR more strongly predicted the risk of NAFLD in the nonobese group than in the obese group. Additionally, the predictive value of VSR for intermediate to high risk of advanced fibrosis was higher in the obese group than in the nonobese group. Future large prospective studies are required to confirm the predictive value of VSR for NAFLD and advanced fibrosis in NAFLD in diverse populations.
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SUPPLEMENTARY MATERIAL
======================

###### Supplemental Table S1.

Prevalence Ratios^a^ (95% CI) of NAFLD by VSR or Visceral Fat or Subcutaneous Fat Quartiles According to Gender after Excluding 157 Subjects with Diabetes

###### Baseline Characteristics by VSR Quartiles

![](enm-35-165-i001)

  Characteristic                     Overall                      VSR quartile                                                                                                      
  ---------------------------------- ---------------------------- -------------------------- ---------------------------- ---------------------------- ---------------------------- ---------
  No. of participants                7465.0                       1953.0                     1832.0                       1848.0                       1832.0                       
  Age, yr                            35.7±7.2                     32.4±5.7                   34.6±6.3                     36.3±7.0                     39.8±7.7                     \<0.001
  Seoul center                       36.7                         31.0                       31.5                         36.7                         47.8                         \<0.001
  Men, %                             74.1                         37.5                       72.2                         91.6                         97.3                         \<0.001
  Alcohol intakea, %                 35.4                         25.0                       34.0                         40.5                         42.5                         \<0.001
  Current smoker, %                  17.5                         9.0                        16.1                         21.5                         23.7                         \<0.001
  Education levelb, %                90.3                         84.8                       90.5                         92.2                         93.9                         \<0.001
  Diabetes, %                        2.1                          0.4                        1.3                          2.5                          4.3                          \<0.001
  Hypertension, %                    9.1                          4.5                        6.4                          10.9                         14.7                         \<0.001
  SBP, mm Hg                         110.1±11.3                   105.7±11.5                 109.5±10.6                   112.7±10.9                   113.0±10.4                   \<0.001
  DBP, mm Hg                         69.9±8.9                     66.1±8.2                   68.5±8.3                     71.6±8.7                     73.5±7.5                     \<0.001
  FPG, mg/dL                         92.6±11.7                    89.7±7.5                   92.0±9.8                     93.8±13.9                    95.0±13.9                    \<0.001
  TC, mg/dL                          196.1±35.0                   187.7±32.8                 194.7±33.8                   199.9±35.7                   202.7±35.8                   \<0.001
  LDL-C, mg/dL                       128.6±33.4                   115.9±30.5                 127.8±32.0                   134.2±33.6                   137.3±33.5                   \<0.001
  HDL-C, mg/dL                       57.3±15.2                    65.8±16.2                  57.4±14.3                    53.6±12.8                    51.7±12.9                    \<0.001
  Triglycerides, mg/dL               97 (68--144)                 71 (55--97)                94 (68--133)                 112 (80--160)                128 (89--177)                \<0.001
  AST, U/L                           20 (17--26)                  18 (16--22)                20 (17--25)                  21 (18--27)                  22 (18--28)                  \<0.001
  ALT, U/L                           21 (15--33)                  15 (11--23)                21 (15--31)                  24 (17--37)                  26 (19--40)                  \<0.001
  GGT, U/L                           23 (15--37)                  15 (12--22)                21 (15--33)                  26 (18--42)                  31 (21--47)                  \<0.001
  hs-CRP, mg/L                       0.5 (0.3--0.9)               0.3 (0.2--0.7)             0.4 (0.3--0.9)               0.5 (0.3--1.0)               0.6 (0.3--1.1)               \<0.001
  HOMA-IR                            1.30 (0.89--1.90)            1.18 (0.79--1.72)          1.30 (0.89--1.89)            1.39 (0.94--2.02)            1.35 (0.94--1.95)            \<0.001
  Platelets, ×10^3^/mm^3^            250 (220--285)               254 (221--289)             248 (220--285)               250 (219--282)               248 (218--285)               0.003
  Total energy intake, kcal/day^c^   1,359.3 (1,030.9--1,758.8)   1,242.8 (895.9--1,652.7)   1,383.4 (1,031.8--1,784.7)   1,435.4 (1,125.8--1,828.7)   1,384.9 (1,091.3--1,776.0)   \<0.001
  FIB-4                              0.68±0.28                    0.63±0.24                  0.66±0.25                    0.68±0.29                    0.75±0.30                    \<0.001
  APRI                               0.25±0.17                    0.24±0.12                  0.25±0.18                    0.26±0.22                    0.26±0.15                    \<0.001

Values are expressed as mean±standard deviation, percentage, or median (interquartile range).

VSR, visceral-to-subcutaneous fat ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; hs-CRP, high-sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance; FIB-4, fibrosis-4 score; APRI, aspartate aminotransferase-to-platelet ratio index; SD, standard deviation.

^a^≥10 g of ethanol per day; ^b^College graduate or higher; ^c^Among 5,523 participants with plausible estimated energy intake (within 3 SDs of the log-transformed mean energy intake).

###### Prevalence Ratios^a^ (95% CI) of Nonalcoholic Fatty Liver Disease by Quartiles of VSR, Subcutaneous Fat, and Visceral Fat

![](enm-35-165-i002)

  Variable                     Number   Case    Age/sex-adjusted PR^a^ (95% CI)   Multivariate-adjusted PRa   
  ---------------------------- -------- ------- --------------------------------- --------------------------- ----------------------
  VSR quartiles                                                                                               
   Q1 (\<0.37)                 1,953    295     1.00 (reference)                  1.00 (reference)            1.00 (reference)
   Q2 (0.37--0.51)             1,832    575     1.40 (1.23--1.59)                 1.38 (1.22--1.56)           1.54 (1.37--1.74)
   Q3 (0.52--0.70)             1,848    844     1.67 (1.47--1.89)                 1.61 (1.42--1.82)           1.95 (1.75--2.19)
   Q4 (≥0.71)                  1,832    992     1.75 (1.54--1.99)                 1.67 (1.47--1.90)           2.24 (1.99--2.52)
   *P* for trend                                \<0.001                           \<0.001                     \<0.001
  Subcutaneous fat quartiles                                                                                  
   Q1 (\<6,058)                1,867    256     1.00 (reference)                  1.00 (reference)            1.00 (reference)
   Q2 (6,058--9,142)           1,866    535     1.94 (1.71--2.21)                 1.91 (1.69--2.17)           1.60 (1.41--1.82)
   Q3 (9,143--12,597)          1,866    801     2.83 (2.52--3.19)                 2.73 (2.42--3.07)           1.96 (1.73--2.22)
   Q4 (≥12,598)                1,866    1,114   4.03 (3.59--4.51)                 3.83 (3.42--4.30)           1.90 (1.65--2.18)
   *P* for trend                                \<0.001                           \<0.001                     \<0.001
  Visceral fat quartiles                                                                                      
   Q1 (\<13,589)               1,868    48      1.00 (reference)                  1.00 (reference)            1.00 (reference)
   Q2 (13,589--17,302)         1,865    383     7.20 (5.32--9.75)                 7.14 (5.27--9.66)           5.73 (4.24--7.73)
   Q3 (17,303--21,834)         1,866    869     15.60 (11.54--21.10)              15.31 (11.33--20.70)        10.63 (7.87--14.36)
   Q4 (≥21,835)                1,866    1,406   24.85 (18.37--33.61)              24.22 (17.90--32.76)        13.74 (10.12--18.65)
   *P* for trend                                \<0.001                           \<0.001                     \<0.001

VSR, visceral-to-subcutaneous fat ratio; CI, confidence interval; PR, prevalence ratio.

^a^Estimated from Poisson regression with robust error. Multivariable model 1: age, sex, center, year of screening examination, smoking status, physical activity, alcohol intake, education level, history of cardiovascular disease, history of diabetes, and history of hypertension; model 2: model 1 plus adjustment for body mass index and homeostasis model assessment of insulin resistance.

###### Prevalence Ratios^a^ (95% CI) of NAFLD and Degree of Fibrosis Based on FIB-4 Score by VSR Quartiles
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  VSR quartile                    Number   Case   Age/sex-adjusted PR^a^ (95% CI)   Multivariate-adjusted PR^a^   
  ------------------------------- -------- ------ --------------------------------- ----------------------------- ---------------------
  NAFLD+low FIB-4                                                                                                 
   Q1 (\<0.37)                    1,953    293    1.00 (reference)                  1.00 (reference)              1.00 (reference)
   Q2 (0.37--0.51)                1,832    569    1.52 (1.28--1.81)                 1.51 (1.27--1.80)             2.23 (1.80--2.76)
   Q3 (0.52--0.70)                1,848    826    2.07 (1.74--2.45)                 2.00 (1.67--2.38)             3.80 (3.04--4.73)
   Q4 (≥0.71)                     1,832    943    2.31 (1.92--2.77)                 2.19 (1.81--2.64)             5.26 (4.15--6.68)
   *P* for trend                                  \<0.001                           \<0.001                       \<0.001
  NAFLD+intermediate/high FIB-4                                                                                   
   Q1 (\<0.37)                    1,953    2      1.00 (reference)                  1.00 (reference)              1.00 (reference)
   Q2 (0.37--0.51)                1,832    6      1.70 (0.34--8.59)                 2.05 (0.40--10.67)            3.38 (0.64--17.97)
   Q3 (0.52--0.70)                1,848    18     3.48 (0.76--15.89)                4.45 (0.93--21.20)            9.41 (1.97--45.01)
   Q4 (≥0.71)                     1,832    48     5.79 (1.28--26.14)                7.40 (1.56--35.06)            19.34 (4.06--92.18)
   *P* for trend                                  \<0.001                           \<0.001                       \<0.001

CI, confidence interval; NAFLD, nonalcoholic fatty liver disease; FIB-4, fibrosis-4; VSR, visceral-to-subcutaneous fat ratio; PR, prevalence ratio.

^a^Estimated from multinomial logistic regression models as outcomes categorized as no NAFLD, NAFLD plus low FIB-4, and NAFLD plus intermediate/high FIB-4. Multivariable model 1 was adjusted for age, sex, center, year of screening examination, smoking status, physical activity, alcohol intake, total energy intake, education level, history of cardiovascular disease, history of diabetes, and history of hypertension; model 2: model 1 plus adjustment for body mass index and homeostasis model assessment of insulin resistance.

###### Prevalence Ratios^a^ (95% CI) of NAFLD and Degree of Fibrosis Based on APRI by VSR Quartiles
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  VSR quartile                   Number   Case   Age/sex-adjusted PR^a^ (95% CI)   Multivariate-adjusted PR^a^   
  ------------------------------ -------- ------ --------------------------------- ----------------------------- ---------------------
  NAFLD+low APRI                                                                                                 
   Q1 (\<0.37)                   1,953    279    1.00 (reference)                  1.00 (reference)              1.00 (reference)
   Q2 (0.37--0.51)               1,832    526    1.46 (1.23--1.74)                 1.45 (1.21--1.73)             2.14 (1.72--2.65)
   Q3 (0.52--0.70)               1,848    789    2.03 (1.70--2.42)                 1.96 (1.64--2.35)             3.67 (2.94--4.58)
   Q4 (≥0.71)                    1,832    903    2.22 (1.85--2.68)                 2.10 (1.73--2.55)             4.99 (3.93--6.33)
   *P* for trend                                 \<0.001                           \<0.001                       \<0.001
  NAFLD+intermediate/high APRI                                                                                   
   Q1 (\<0.37)                   1,953    16     1.00 (reference)                  1.00 (reference)              1.00 (reference)
   Q2 (0.37--0.51)               1,832    49     2.46 (1.37--4.42)                 2.56 (1.42--4.63)             5.04 (2.65--9.59)
   Q3 (0.52--0.70)               1,848    55     2.67 (1.47--4.84)                 2.70 (1.48--4.93)             7.51 (3.91--14.42)
   Q4 (≥0.71)                    1,832    89     4.53 (2.50--8.21)                 4.71 (2.56--8.66)             19.55 (9.97--38.34)
   *P* for trend                                 \<0.001                           \<0.001                       \<0.001

CI, confidence interval; NAFLD, nonalcoholic fatty liver disease; APRI, aspartate aminotransferase-to-platelet ratio index; VSR, visceral-to-subcutaneous fat ratio; PR, prevalence ratio.

^a^Estimated from multinomial logistic regression models as outcomes categorized as no NAFLD, NAFLD plus low APRI, and NAFLD plus intermediate/high APRI. Multivariable model 1 was adjusted for age, sex, center, year of screening examination, smoking status, physical activity, alcohol intake, total energy intake, education level, history of cardiovascular disease, history of diabetes, and history of hypertension; model 2: model 1 plus adjustment for body mass index and homeostasis model assessment of insulin resistance.

###### Prevalence Ratios^a^ (95% CI) of NAFLD or NAFLD and Degree of Fibrosis by VSR Quartiles According to Obesity
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  VSR quartile                                  Multivariate-adjusted PR   *P* for interaction   
  --------------------------------------------- -------------------------- --------------------- ---------
  NAFLD                                                                                          
   Q1 (\<0.37)                                  1.00 (reference)           1.00 (reference)      \<0.001
   Q2 (0.37--0.51)                              2.93 (2.15--4.00)          1.23 (1.10--1.38)     
   Q3 (0.52--0.70)                              4.57 (3.37--6.21)          1.43 (1.29--1.59)     
   Q4 (≥0.71)                                   6.52 (4.81--8.82)          1.38 (1.24--1.53)     
   *P* for trend                                \<0.001                    \<0.001               
  NAFLD and degree of fibrosis based on FIB-4                                                    
   NAFLD+low FIB-4                                                                               \<0.001
    Q1 (\<0.37)                                 1.00 (reference)           1.00 (reference)      
    Q2 (0.37--0.51)                             2.81 (2.00--3.95)          \-                    
    Q3 (0.52--0.70)                             4.56 (3.26--6.40)          \-                    
    Q4 (≥0.71)                                  7.16 (5.09--1.07)          \-                    
    *P* for trend                               \<0.001                    \<0.001               
   NAFLD+intermediate/high FIB-4                                                                 
    Q1 (\<0.37)                                 1.00 (reference)           1.00 (reference)      
    Q2 (0.37--0.51)                             1.61 (1.27--2.03)          2.90 (0.53--15.92)    
    Q3 (0.52--0.70)                             2.78 (2.18--3.56)          7.33 (1.48--36.28)    
    Q4 (≥0.71)                                  2.70 (2.08--3.51)          8.79 (1.80--43.06)    
    *P* for trend                               0.003                      \<0.001               
  NAFLD and degree of fibrosis based on APRI                                                     
   NAFLD+low APRI                                                                                \<0.001
    Q1 (\<0.37)                                 1.00 (reference)           1.00 (reference)      
    Q2 (0.37--0.51)                             2.74 (1.95--3.85)          \-                    
    Q3 (0.52--0.70)                             4.38 (3.13--6.15)          \-                    
    Q4 (≥0.71)                                  6.75 (4.80--9.50)          \-                    
    *P* for trend                               \<0.001                    \<0.001               
   NAFLD+intermediate/high APRI                                                                  
    Q1 (\<0.37)                                 1.00 (reference)           1.00 (reference)      
    Q2 (0.37--0.51)                             1.51 (1.19--1.92)          3.14 (1.72--5.74)     
    Q3 (0.52--0.70)                             2.70 (2.10--3.46)          4.47 (2.41--8.29)     
    Q4 (≥0.71)                                  2.53 (1.94--3.31)          7.01 (3.72--13.21)    
    *P* for trend                               \<0.001                    \<0.001               

CI, confidence interval; NAFLD, nonalcoholic fatty liver disease; VSR, visceral-to-subcutaneous fat ratio; PR, prevalence ratio; FIB-4, fibrosis-4; APRI, aspartate aminotransferase-to-platelet ratio index.

^a^Estimated from Poisson regression with robust error. The multivariable model was adjusted for age, sex, center, year of screening examination, smoking status, physical activity, alcohol intake, total energy intake, education level, history of cardiovascular disease, history of diabetes, and history of hypertension.

[^1]: ^\*^These authors contributed equally to this work.
